Glioblastoma (GBM) is an aggressive and lethal type of brain tumor in human adults. The
standard of care offers minimal clinical benefit, and most GBM patients experience tumor …

Glioblastoma (GBM) is characterized by aggressive growth and high rates of recurrence.
Despite the advancements in conventional therapies, the prognosis for GBM patients …

PURPOSE An ASCO provisional clinical opinion offers timely clinical direction to ASCO's
membership following publication or presentation of potentially practice-changing data from …

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor
with a high mortality rate. Immunotherapy has achieved promising clinical results in multiple …

In comparison with responses in recurrent glioblastoma (rGBM), the intracranial response of
brain metastases (BrM) to immune checkpoint blockade (ICB) is less well studied. Here, we …

Simple Summary Glioblastoma is the most common malignant brain tumor associated with a
poor prognosis, with a median survival of 14 months. Despite initial treatment with surgery …

Durable objective response rate (ORR) remains a meaningful endpoint in recurrent cancer;
however, the target ORR for single-arm recurrent glioblastoma trials has not been based on …

Increasing evidence suggests that the gut microbiome plays a key role in a host of
pathological conditions, including cancer. Indeed, the bidirectional communication that …

Simple Summary There are few established treatment options for recurrent glioblastoma
(rGBM). Immunotherapy, which potentiates the immune system to counter tumor growth …

Cancer is one of the main causes of human mortality and brain tumors, including invasive
pituitary adenomas, medulloblastomas and glioblastomas are common brain malignancies …